Samsung Biologics Achieves EcoVadis Platinum Sustainability Rating
Event summary
- Samsung Biologics received the EcoVadis Platinum Sustainability Rating, placing it in the top 1% of companies assessed globally.
- The rating reflects progress across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement categories.
- Samsung Biologics previously held a Gold rating in 2024, demonstrating sustained improvement in sustainability practices.
- The company received an 'A' rating in Water Security from the CDP in December 2025.
- Samsung Biologics is set to acquire a manufacturing facility in Rockville, Maryland, U.S., adding 60,000 liters of biomanufacturing capacity.
The big picture
Samsung Biologics' EcoVadis Platinum rating underscores the growing importance of sustainability in the contract manufacturing sector. As global pharmaceutical companies increasingly prioritize ESG criteria in supplier selection, Samsung Biologics positions itself as a leader in responsible biomanufacturing. The company's sustained improvement in sustainability metrics reflects broader industry trends toward transparent, ethical supply chains and resilient value chains.
What we're watching
- ESG Momentum
- How Samsung Biologics will leverage its Platinum rating to attract ESG-focused pharmaceutical partners.
- Operational Expansion
- The pace at which the Rockville facility acquisition will integrate and contribute to sustainability goals.
- Supply Chain Resilience
- Whether the company's decarbonization efforts will set a new benchmark for the CDMO industry.
Related topics